Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
02 Maio 2023 - 5:30PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
changing the possible for patients through engineered cells, today
announced that six abstracts highlighting preclinical data
from the fusogen platform have been accepted for presentation,
including two oral presentations, at the American Society of Gene
and Cell Therapy (ASGCT) 26th Annual Meeting taking place May
16-20, 2023 in Los Angeles, CA.
Oral Presentations:
Title: |
A Novel Technique to Detect Peripheral Blood CAR+ T Cells
Using RNAscope In Situ Hybridization (ISH) in
Non-Human Primates and Mice |
Summary: |
A novel cell-block method can be
used to detect circulating CAR T cells in preclinical studies by
evaluating the expression of Woodchuck Hepatitis Virus
Posttranscriptional Regulatory Element (WPRE) by Fluorescence in
situ hybridization (FISH) in lieu of flow cytometry or PCR. |
Session: |
Pharmacology/Toxicology Studies:
Bio Distribution |
Session
Location: |
Petree Hall C |
Session
Date/Time: |
Friday, May 19, 2023; 3:45 p.m. –
5:30 p.m. PT |
Presentation
Time: |
5:00 p.m. – 5:15 p.m. PT |
Abstract
Number: |
240 |
|
|
Title: |
Target Cell and Tissue
Specificity of a Novel CD8-Targeted Fusosome
for Direct In Vivo
Delivery of CD19 or a CD20 CAR to CD8+ T
Cells |
Summary: |
A panel of in vitro studies
confirmed cell-specific transduction, CAR Expression, and target
cell killing, supporting safe in vivo administration of Sana’s
novel CD8-directed fusosomes for CAR T therapies. |
Session: |
Pharmacology/Toxicology Studies:
In Vitro and In Vivo Safety |
Session
Location: |
Petree Hall C |
Session
Date/Time: |
Saturday, May 20, 2023; 8:00 a.m.
– 9:45 a.m. PT |
Presentation
Time: |
9:15 a.m. – 9:30 a.m. PT |
Abstract
Number: |
317 |
|
|
Poster Presentations:
Title: |
Advancements in Manufacturing of CD8-Targeted Fusosomes
Enhance Transduction of Resting T
Cells In Vitro and
In Vivo |
Summary: |
Process improvements were made to
the manufacturing of Sana’s CD8 targeted fusosome for in vivo CAR T
therapy, resulting in enhanced resting T cell transduction and in
vitro and in vivo tumor killing. |
Session: |
Wednesday Poster Session |
Session
Date/Time: |
Wednesday, May 17, 2023; 12:00
p.m. PT |
Abstract
Number: |
760 |
|
|
Title: |
Temsirolimus and IL-7
Treatment Synergistically Increase
Primary Resting CD8+ T Cell Transduction with
CD8-Targeted Fusosomes and Enhance CD19CAR
Expression |
Summary: |
The use of IL-7 and Rapamycin
analogs (Rapalogs) with Sana’s CD8 targeted fusosomes is able to
increase fusosome potency and improves the ability to deliver a
therapeutic CAR transgene. |
Session: |
Thursday Poster Session |
Session
Date/Time: |
Thursday, May 18, 2022; 12:00
p.m. PT |
Abstract
Number: |
1058 |
|
|
Title: |
In Vivo
Delivery of Genetic Payloads to Human
Hematopoietic Stem/Progenitor
Cells |
Summary: |
A robust strategy for
establishing basal access and achieving efficient and specific in
vivo delivery of genetic payloads to human hematopoietic stem and
progenitor cells (HSPC) was established. |
Session: |
Thursday Poster Session |
Session
Date/Time: |
Thursday, May 18, 2023; 12:00
p.m. PT |
Abstract
Number: |
1017 |
|
|
Title: |
The Retargeted Universal
Fusosome: A Modular Approach to
Generate Fusosomes for Targeted Gene
Delivery |
Summary: |
A modular approach to developing
retargetable fusosomes decouples production and targeting, offering
an efficient method to identify potent candidates for cell-specific
gene delivery. |
Session: |
Thursday Poster Session |
Session
Date/Time: |
Thursday, May 18, 2023; 12:00
p.m. PT |
Abstract
Number: |
970 |
|
|
The ASGCT abstracts are available to the public at:
https://annualmeeting.asgct.org.
About Sana BiotechnologySana
Biotechnology, Inc. is focused on creating and delivering
engineered cells as medicines for patients. We share a vision of
repairing and controlling genes, replacing missing or damaged
cells, and making our therapies broadly available to patients. We
are a passionate group of people working together to create an
enduring company that changes how the world treats disease. Sana
has operations in Seattle, Cambridge, South San Francisco, and
Rochester. For more information about Sana Biotechnology, please
visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision; expectations for
the Company’s participation at the American Society of Gene and
Cell Therapy 26th Annual Meeting; and expectations for the
Company’s presentations at such meeting, including the content of
such presentations. and expectations for its development programs,
product candidates and technology platforms, including with respect
to clinical trials and expected timing and impact thereof; and
expectations for hosting a potential R&D Day event, including
the timing of and subject matter of the presentations at such
event. All statements other than statements of historical facts
contained in this press release, including, among others,
statements regarding the Company’s strategy, expectations, cash
runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as economic,
market, and other disruptions, including due to the COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Annual Report on Form 10-K dated March 16, 2023.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Investor Relations &
Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sana Biotechnology (NASDAQ:SANA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024